Soleus Capital Management »

ImmunoGen shares owned by Soleus Capital Management

Quarter-by-quarter ownership of ImmunoGen shares owned by Soleus Capital Management from 13F filings

Historical chart of Soleus Capital Management investment in ImmunoGen

Tip: Access up to 7 years of quarterly data

All positions including ImmunoGen held by Soleus Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in ImmunoGen by Soleus Capital Management

Quarter filed Position value Share count Share price at filing
2023-12-31 $387k 13k 29.65

More positions owned by Soleus Capital Management

Teva Pharmaceutical Inds Sponsored Ads (TEVA)
United Therapeutics Corporation (UTHR)
GSK Sponsored Adr (GSK)
Rayzebio
Edap Tms S A Sponsored Adr (EDAP)
Organogenesis Hldgs (ORGO)
Humana (HUM)
Celcuity (CELC)
Iradimed (IRMD)
Essa Pharma Com New (EPIX)
SurModics (SRDX)
Hca Holdings (HCA)
Vaxcyte (PCVX)
Neuropace (NPCE)
Nuvalent Inc-a (NUVL)

View all positions for Soleus Capital Management

Top funds holding ImmunoGen

Vanguard Group
RA Capital Management
Redmile Group
Henderson Group
Pentwater Capital Management
Fairmount Funds Management
Norges Bank Investment Management
Millennium Management
D. E. Shaw & Co
Balyasny Asset Management
Voloridge Investment Management
Boxer Capital
Maverick Capital
TIG Advisors
Tang Capital Management

View all funds holding ImmunoGen